Cargando…
Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome
Several problems such as myalgia, arthralgia, fever, dyspnea, generalized edema, and pleural effusion can occur in cancer patients following the chemotherapy, especially at the first cycle of the first chemotherapy treatment. Although it is assumed that some cytokines are associated with the develop...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558530/ https://www.ncbi.nlm.nih.gov/pubmed/31217693 http://dx.doi.org/10.1177/1179299X19854447 |
_version_ | 1783425645381943296 |
---|---|
author | Keskin, Havva Cadirci, Kenan Demirkazik, Ahmet Akbulut, Hakan Yalcin, Bulent |
author_facet | Keskin, Havva Cadirci, Kenan Demirkazik, Ahmet Akbulut, Hakan Yalcin, Bulent |
author_sort | Keskin, Havva |
collection | PubMed |
description | Several problems such as myalgia, arthralgia, fever, dyspnea, generalized edema, and pleural effusion can occur in cancer patients following the chemotherapy, especially at the first cycle of the first chemotherapy treatment. Although it is assumed that some cytokines are associated with the development of these symptoms and signs, their pathophysiology has not been discovered completely yet. They are usually mild, but they may rarely progress to the severe stage of “Systemic Capillary Leak Syndrome” with a high mortality rate. The objective of this study was to investigate the association between the serum levels of interleukin-2 (IL-2), interleukin-11 (IL-11), tumor necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF), and these symptoms and signs. A total of 44 cancer patients who had neither heart, lung, liver, renal, or thyroid disease were recruited into this study. Their symptoms and signs were examined and questioned before the first cycle of the first chemotherapy treatment and the 24 h after this chemotherapy. All participant’s serum samples were taken, and the VEGF, TNF, IL-2, and IL-11 levels were studied. There was no association between the chemotherapeutic drugs, and the symptoms and signs such as edema, dyspnea, coughing, and flu-like symptoms. There was a significant decrease in IL-11 levels in the other treatment group compared with the group receiving paclitaxel, docetaxel, gemcitabine, and vinorelbine in the first day following chemotherapy (P = .006). However, no relation was observed between the symptoms and signs, the response to the chemotherapy, and the serum levels of VEGF, TNF, IL-2, and IL-11. These symptoms and life-threatening syndrome have been a current topic between the clinicians. Although some drugs and mediators are accused, its pathophysiology has not been discovered completely yet. In this study, we could not detect any association between the symptoms, signs, and the cytokine levels following the chemotherapy. |
format | Online Article Text |
id | pubmed-6558530 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-65585302019-06-19 Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome Keskin, Havva Cadirci, Kenan Demirkazik, Ahmet Akbulut, Hakan Yalcin, Bulent Biomark Cancer Original Research Several problems such as myalgia, arthralgia, fever, dyspnea, generalized edema, and pleural effusion can occur in cancer patients following the chemotherapy, especially at the first cycle of the first chemotherapy treatment. Although it is assumed that some cytokines are associated with the development of these symptoms and signs, their pathophysiology has not been discovered completely yet. They are usually mild, but they may rarely progress to the severe stage of “Systemic Capillary Leak Syndrome” with a high mortality rate. The objective of this study was to investigate the association between the serum levels of interleukin-2 (IL-2), interleukin-11 (IL-11), tumor necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF), and these symptoms and signs. A total of 44 cancer patients who had neither heart, lung, liver, renal, or thyroid disease were recruited into this study. Their symptoms and signs were examined and questioned before the first cycle of the first chemotherapy treatment and the 24 h after this chemotherapy. All participant’s serum samples were taken, and the VEGF, TNF, IL-2, and IL-11 levels were studied. There was no association between the chemotherapeutic drugs, and the symptoms and signs such as edema, dyspnea, coughing, and flu-like symptoms. There was a significant decrease in IL-11 levels in the other treatment group compared with the group receiving paclitaxel, docetaxel, gemcitabine, and vinorelbine in the first day following chemotherapy (P = .006). However, no relation was observed between the symptoms and signs, the response to the chemotherapy, and the serum levels of VEGF, TNF, IL-2, and IL-11. These symptoms and life-threatening syndrome have been a current topic between the clinicians. Although some drugs and mediators are accused, its pathophysiology has not been discovered completely yet. In this study, we could not detect any association between the symptoms, signs, and the cytokine levels following the chemotherapy. SAGE Publications 2019-06-10 /pmc/articles/PMC6558530/ /pubmed/31217693 http://dx.doi.org/10.1177/1179299X19854447 Text en © The Author(s) 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Keskin, Havva Cadirci, Kenan Demirkazik, Ahmet Akbulut, Hakan Yalcin, Bulent Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome |
title | Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor,
Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial
Growth Factor Levels, and the Systemic Symptoms like Capillary Leak
Syndrome |
title_full | Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor,
Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial
Growth Factor Levels, and the Systemic Symptoms like Capillary Leak
Syndrome |
title_fullStr | Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor,
Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial
Growth Factor Levels, and the Systemic Symptoms like Capillary Leak
Syndrome |
title_full_unstemmed | Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor,
Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial
Growth Factor Levels, and the Systemic Symptoms like Capillary Leak
Syndrome |
title_short | Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor,
Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial
Growth Factor Levels, and the Systemic Symptoms like Capillary Leak
Syndrome |
title_sort | following chemotherapy: serum cytokine (tumor necrosis factor,
interleukin-2, interleukin-11), immunoglobulin, complement, vascular endothelial
growth factor levels, and the systemic symptoms like capillary leak
syndrome |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558530/ https://www.ncbi.nlm.nih.gov/pubmed/31217693 http://dx.doi.org/10.1177/1179299X19854447 |
work_keys_str_mv | AT keskinhavva followingchemotherapyserumcytokinetumornecrosisfactorinterleukin2interleukin11immunoglobulincomplementvascularendothelialgrowthfactorlevelsandthesystemicsymptomslikecapillaryleaksyndrome AT cadircikenan followingchemotherapyserumcytokinetumornecrosisfactorinterleukin2interleukin11immunoglobulincomplementvascularendothelialgrowthfactorlevelsandthesystemicsymptomslikecapillaryleaksyndrome AT demirkazikahmet followingchemotherapyserumcytokinetumornecrosisfactorinterleukin2interleukin11immunoglobulincomplementvascularendothelialgrowthfactorlevelsandthesystemicsymptomslikecapillaryleaksyndrome AT akbuluthakan followingchemotherapyserumcytokinetumornecrosisfactorinterleukin2interleukin11immunoglobulincomplementvascularendothelialgrowthfactorlevelsandthesystemicsymptomslikecapillaryleaksyndrome AT yalcinbulent followingchemotherapyserumcytokinetumornecrosisfactorinterleukin2interleukin11immunoglobulincomplementvascularendothelialgrowthfactorlevelsandthesystemicsymptomslikecapillaryleaksyndrome |